<html>
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Document</title>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.0/dist/css/bootstrap.min.css"
	integrity="sha384-B0vP5xmATw1+K9KRQjQERJvTumQW0nPEzvF6L/Z6nronJ3oUOFUFpCjEUQouq2+l" crossorigin="anonymous">

<body>

	<div class="header">
		<nav class="navbar navbar-expand-lg navbar-dark bg-dark">
			<div class="container-fluid">
				<a class="navbar-brand" href="#"><img src="../../../../images/logopng.png" alt="" height="50px"
						width="50px"></a>
				<button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarNav"
					aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
					<span class="navbar-toggler-icon"></span>
				</button>
				<div class="collapse navbar-collapse" id="navbarNav">
					<ul class="navbar-nav">
						<li class="nav-item">
							<a class="nav-link" aria-current="page" href="../../../index.html">Home</a>
						</li>
						<li class="nav-item">
							<a class="nav-link active" href="../../index.html">HTML</a>
						</li>
						<li class="nav-item">
							<a class="nav-link" href="../../../CSS/index.html">CSS</a>
						</li>
						<li class="nav-item">
							<a class="nav-link" href="../../../Bootstrap/index.html">Bootstrap</a>
						</li>
						<li class="nav-item">
							<a class="nav-link" href="../../../javascript/index.html">JavaScript</a>
						</li>

					</ul>
				</div>
			</div>
		</nav>
	</div>


	<div class="container-fluid">
		<div class="row">
			<div class="col-md-3 bg-dark text-white" style="height: 100vh;">


				<ul>Day3
					<ol>practise exercise


						<li> <a href="../practise exersize/one.html" class="text-white">student report
								card</a></li>

						<li> <a href="Day3/NishiBuch/practise exersize/two.html" class="text-white">latest news</a></li>
						<li> <a href="../practise exersize/three.html" class="text-white">student login
								form</a></li>
						<li> <a href="../practise exersize/four.html" class="text-white">navbar</a></li>
						<li> <a href="../practise exersize/five.html" class="text-white">lists</a></li>



					</ol>
					<ol>assignment

						<li> <a href="../assignment/d3assign.html" class="text-white">loginform
								validation</a></li>

					</ol>

				</ul>

			</div>
			<div class="col-md-9 mt-2">
				<div class="main">
					<h3 class="text-center">Latest News</h3>
					<img src="Images/natural2.JPEG">
					<h2> Japanese approval of Moderna's Covid-19 vaccine As Olympics loom</h2>
					<article>
						<p>
							Moderna Inc`s Covid-19 vaccine is unlikely to win approval in Japan until May due to
							requirements for local
							clinical trials, the distributor said, casting doubt over a nationwide vaccination rollout
							before the summer
							Tokyo Olympics. With an eye on the Olympics due to start in late July, Japan has secured
							rights
							to at least
							540 million doses of Covid-19 vaccines from several Western developers, the biggest quantity
							in
							Asia and
							more than enough for its 126 million population. But Tokyo faces a major regulatory
							bottleneck
							due to
							requirements for local clinical trials before requesting approval. Several other countries
							have
							fast-tracked
							the review process to expedite mass inoculations.


						</p>
						<p>
							Masayuki Imagawa, the head of the Japan vaccine business for Takeda Pharmaceutical Co, told
							Reuters it would
							likely take several more months to complete the trial and said securing approval in May was
							"the
							best case
							scenario". Takeda, Japan`s biggest drugmaker, is a critical component to Prime Minister
							Yoshihide Suga`s aim
							to have enough vaccines for the population by June before the Summer Games, currently
							scheduled
							to start on
							July 23. The company is handling domestic approval and imports of the Moderna shot and local
							production of
							Novavax Inc`s vaccine, whose development and approval in Japan is further off.

							Moderna did not immediately respond to an emailed request for comment.
						</p>
						<p>
							Covid-19 vaccine developed by Oxford University and AstraZeneca Plc is also being trialed in
							Japan, leaving
							a shot developed by Pfizer Inc and BioNTech the only one currently under regulatory review
							in
							the country.
							Japan has arranged to buy 120 million doses each from Pfizer and AstraZeneca. Through
							Takeda, it
							will secure
							50 million doses of the Moderna vaccine and up to 250 million of the Novavax formula.

							

						</p>
					</article>


				</div>
			</div>


		</div>

	</div>
	<script src="https://code.jquery.com/jquery-3.5.1.slim.min.js"
		integrity="sha384-DfXdz2htPH0lsSSs5nCTpuj/zy4C+OGpamoFVy38MVBnE+IbbVYUew+OrCXaRkfj"
		crossorigin="anonymous"></script>
	<script src="https://cdn.jsdelivr.net/npm/popper.js@1.16.1/dist/umd/popper.min.js"
		integrity="sha384-9/reFTGAW83EW2RDu2S0VKaIzap3H66lZH81PoYlFhbGU+6BZp6G7niu735Sk7lN"
		crossorigin="anonymous"></script>
	<script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.0/dist/js/bootstrap.min.js"
		integrity="sha384-+YQ4JLhjyBLPDQt//I+STsc9iw4uQqACwlvpslubQzn4u2UU2UFM80nGisd026JF"
		crossorigin="anonymous"></script>

</body>

</html>